Study to Evaluate Nipocalimab in Participants with Active Idiopathic Inflammatory Myopathies

Brief description of study

The purpose of this study is to see if the investigational drug nipocalimab is safe and useful for treating patients with active Idiopathic Inflammatory Myopathies (IIM). Another purpose is to find out if nipocalimab can cause side effects, which are unexpected or unwanted reactions from taking a drug. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) for treating IIM.

Detailed description of study

We will use your personal health information, information from the tests and procedures done for the study, and information about how the study drug affects you to help determine if the study drug is safe and effective in treating IIM.

You will be randomly assigned to receive either nipocalimab or placebo. A placebo is an inactive substance or other intervention that looks the same as, and is given the same way as, an active drug or treatment being tested. This is a double-blind study, which means that you and the study team will not know which group you are in.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Idiopathic Inflammatory Myopathies,IIM,rheumatology
Age: Between 18 Years - 90 Years
Gender: All

Updated on 09 Mar 2024. Study ID: 852070

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).